LAVA Therapeutics (LVTX) Proxy Filing summary

Executive summary

• The 2025 Annual General Meeting (AGM) is scheduled for June 11, 2025, in Utrecht, Netherlands, with a record date of May 14, 2025. Shareholders can vote in person or by proxy, and a quorum requires at least one-third of issued shares represented.

• The agenda includes adoption of 2024 annual accounts, auditor appointments, board member releases from liability, share repurchase authorization, and director reappointments.

• Proxy materials and annual reports are available online, and shareholders are encouraged to vote prior to the meeting.

Voting matters and shareholder proposals

• Proposals include adoption of Dutch statutory annual accounts for 2024, appointment and ratification of PricewaterhouseCoopers as external auditor for 2025, release of board members from liability for 2024, extension of share repurchase authorization, and reappointment of two non-executive directors.

• All proposals are recommended for approval by the board.

• Shareholder proposals for the 2026 AGM must be submitted by January 22, 2026, and only shareholders with at least 3% of issued capital may submit proposals for the agenda.

Board of directors and corporate governance

• The board consists of eight members: one executive and seven non-executive directors, with staggered three-year terms.

• The chair is an independent non-executive director, and the board structure separates the roles of chair and CEO.

• All committees (Audit, Compensation, Nomination and Corporate Governance) are composed entirely of independent directors.

• The board and committees met regularly in 2024, with all directors attending at least 75% of meetings.

• Director candidates are evaluated based on experience, independence, and diversity of expertise.